Explore SDS Optic

Our Mission

We are committed to addressing unmet diagnostic and general labolatory needs in oncology and infectious diseases by advancing and optimizing current biomarker technologies. Our mission is to improve patient outcomes by providing innovative, biomarker based diagnostic solutions that benefit patients, healthcare providers, and payors alike.

Corporate video

HER2 biomarker overexpression in cancer

HER2-expressing cancers are a group of aggressive tumors often associated with faster progression and a poorer prognosis. These include breast, gastric, lung and a range of other cancers.

While HER2 positivity can accelerate tumor growth, targeted therapies have significantly improved patient outcomes. Accurate assessment of HER2 status is essential for selecting optimal treatments and advancing precision medicine research.

HER2 overexpressing cancers
link to SDS Optic's newsroom
SDS Optic presence on the NewConnect market

We Care About Your Privacy

SDS Optic S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.